Clinical Trial Update: Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma. [Phase 3]

View source ↗

Summary

Phase 3 trial update investigating low molecular weight heparin (LMWH) for preventing thromboembolic complications after transarterial chemoembolization (TACE) …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Low molecular weight heparin (low molecular weight heparin)

Snippet

Sponsor: Sherief Abd-Elsalam | Conditions: HCC | Phase 3 | Status: UNKNOWN